-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WAAAzOrUMPWpzQ2IdeYrzcpu8RQz5oiezN5ijS3JPcc63J+ZCYMRmdjTK1uJaQvB c+2FkczO4//KJeKCg5sFoA== 9999999997-08-027482.txt : 20080606 9999999997-08-027482.hdr.sgml : 20080606 20080606135229 ACCESSION NUMBER: 9999999997-08-027482 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20080606 DATE AS OF CHANGE: 20080606 20080606 20080606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVANIR PHARMACEUTICALS CENTRAL INDEX KEY: 0000858803 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330314804 STATE OF INCORPORATION: CA FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-15803 FILM NUMBER: 08885137 BUSINESS ADDRESS: STREET 1: 101 ENTERPRISE STREET 2: SUITE 300 CITY: ALISO VIEJO STATE: CA ZIP: 92656 BUSINESS PHONE: 949-389-6700 MAIL ADDRESS: STREET 1: 101 ENTERPRISE STREET 2: SUITE 300 CITY: ALISO VIEJO STATE: CA ZIP: 92656 FORMER COMPANY: FORMER CONFORMED NAME: LIDAK PHARMACEUTICALS DATE OF NAME CHANGE: 19920703 CT ORDER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C0-)>+CS],-"C8@,"!O8FH@/#PO3&EN96%R:7IE9"`Q+TP@-S@S M-"]/(#@O12`S-C@U+TX@,2]4(#7!E+U!A9V4^/@UE;F1O8FH-.2`P(&]B:CP\+T9O;G0\/"]45#(@,3`@,"!2 M+U14-"`Q,B`P(%(^/B]0A3'#O`(#Z,F`,V M_N'#M:<0V"$-/8A/(QN>\#].Y=?SB(`5_X?#":/,AWAA)N(_S6#BTBCT+\L3 MF]HV"Y6]&3V/'LC]9ATOK8E'0[*`G37QZ93$EDT=,HOU]'('UC_QM]%D2H/P M"@_],WAR)/%VR_G]=AVO+=SN2=O99@%X@(NX?\^_SC8WY@7F=[>WZ]UN?;?1 M^"%E[!J>]?!,Q?RM+3A,Q^#8=JBC9#YUO4&8UP3Y-)I>HT8]:J2=OMLNEENX ML2;H`]G.-O%Z90S\.$]/9.9^\[VGZ]6*+-[#O$V^4LOL470QF: M3OVA=\9<,R\/C;\NH>,,V5H:CF`VC^%N!2QR94X]C]J(ZO:TNB4G@8[`NQQL7W&D=*4E:^@":^($OHW*&<9DA:BR M06!UN]=SHFEX!DD!R?F-BN@=Y72L$'I`)1 M=!,,ORN]3WI6@&B`_TXUE(7'1:3-N%9?1%V4D-U3$URH,1YE<*A*&;9/H#ER M6/X^BKUH:FA*2&!55F:-V9._X(`IS3IY:NS7U+,>WQ0=NG>;O`#S=-W1KL]< M:\]0-@!@;)@[1KXD-9Z->!4_5[Q&BE3T*NP:]B_0IU:'CEX'@]#9!1D+4B%K M"41#"33'I,$O42.L2R3I9;=)46U"U]BO0_RRY M_`4R4:=Y67.4-P7=GVP:3@=BOA;;`YFE:5EE6(?YRUC61(Z%D'59#&06NZ;L MLV%9A!19Z##&V/B@H) ME_7I$=1PSA,4&4'W,.CFJ%=-]'B4SFXC]/F=V9E7HLR@/O-4BBQ35I\O3>>C MHL+.Z47FS@+HZAPLV1@)4LO`8I&GND!5MD]'LR*KU^S!&M8C1W8/=:ANO=Z[ MU\EU6WZ;+M.6R.(,_V;"/XT#.)-V,H?ZK?#AH7.KWY^[]K6D_Z/71 M>;#K/#AKD-XV[0;BS?D#-&4S5P=W;K3RX9-"O]5R;_2N4[TO!%Z1J-E:QJ/_ M!1@`Q.6N>PH-"F5N9'-T7!E M+U1R=654>7!E+T9O;G1$97-C%LM-38X("TS,#<@,C`P,"`Q,#`W72]!7!E+T9O;G1$97-C7!E+T5X=$=3=&%T92]302!F86QS92]332`P+C`R/CX-96YD;V)J#3$@,"!O M8FH\/"].=6US6S`@,B`P(%)=/CX-96YD;V)J#3(@,"!O8FH\/"]3+T0^/@UE M;F1O8FH-,R`P(&]B:CP\+T-O=6YT(#$O5'EP92]086=EG)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM M;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2(S+C$M-S`Q(CX*("`@ M/')D9CI21$8@>&UL;G,Z&UL;G,Z<&1F/2)H='1P.B\O;G,N M861O8F4N8V]M+W!D9B\Q+C,O(CX*("`@("`@("`@/'!D9CI0&%P+S$N,"\B/@H@("`@("`@("`\>&%P.D-R96%T M;W)4;V]L/E!38W)I<'0U+F1L;"!697)S:6]N(#4N,BXR/"]X87`Z0W)E871O M&UL;G,Z9&,] M(FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT"UD969A=6QT(CY-:6-R;W-O9G0@ M5V]R9"`M($%V86YI&%P34TZ26YS=&%N8V5) M1#YU=6ED.C8W8V5A-V$X+3$W968M-#AE-RUA-V,X+3`V,S4X.&%C831F8CPO M>&%P34TZ26YS=&%N8V5)1#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@ M(#POF4@-CX^#0IS=&%R='AR968-"C$Q-@T*)25% $3T8-"C\_ ` end -----END PRIVACY-ENHANCED MESSAGE-----